Marinomed Biotech AG (VIE:MARI)

Market Cap	32.20M +25.7%
Revenue (ttm)	9.76M +47.4%
Net Income	9.12M
EPS	5.13
Shares Out	1.84M
PE Ratio	3.41
Forward PE	1.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112
Average Volume	997
Open	17.20
Previous Close	17.50
Day's Range	17.20 - 17.50
52-Week Range	11.70 - 21.00
Beta	-0.31
RSI	47.20
Earnings Date	Apr 22, 2026

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 33
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI

Financial Performance

In 2024, Marinomed Biotech AG's revenue was 4.79 million, a decrease of -49.01% compared to the previous year's 9.40 million. Losses were -15.42 million, 142.2% more than in 2023.